If you’re not tracking diversity data early, you’re tracking it too late.

It’s not uncommon to collect diversity data in clinical trials post-consent or post-randomization. But consider this: By the time you see that your trial is not on track to meet your FDA Race and Ethnicity Diversity Plan, it’s too late to correct your recruitment and enrollment strategy.

Shared technology between sites and sponsors is the key to monitoring patient diversity data early enough that you have plenty of time to:

1. identify diversity challenges during enrollment;
2. remove any barriers to enrolling a representative population for your trial.

That’s why StudyTeam® for Sites makes it easy for sites to document patient race and ethnicity details during recruitment and pre-screening, and StudyTeam for Sponsors makes it easy for you to visualize whether a representative population is enrolling and, if it’s not, why.

Implement a strategy to track and measure diversity data in your trials. 

To keep timelines and goals on track across your portfolio, ensure each of your trials is strategically set up to collect pre-enrollment patient diversity data, so you can take action early when diversity goals are at risk.

Save time with StudyTeam. Set your trial up to meet your diversity goals.

"StudyTeam is really unique because it’s the vessel that can carry data from sites to sponsors before enrollment,” said Alan Lane, Senior Director of Strategic Accounts at OneStudyTeam.

Replies to this inbox are not monitored. Please contact us with any questions.